You don't often see a "science day" in a Philadelphia courtroom. But that's exactly what happened last week in a potentially ...

Ozempic and licensed weight loss drugs may come with an overlooked risk, dietitians have warned. Aside from the potential side effects and physical changes that one can expect from starting a new ...

A woman who used the semaglutide drugs Wegovy and Ozempic to lose weight and treat diabetes says the drugmaker didn’t ...

In our content, we occasionally include affiliate links. Should you click on these links, we may earn a commission, though this incurs no additional cost to you. Your use of this website signifies ...

Some patients taking weight-loss drugs, like Ozempic, are beginning to report slower or no weight loss as their bodies build ...

Analysts believe Hims & Hers will earn $0.57 per share this year and $0.80 next year. That prices the stock at 17 times next ...

Ozempic, Wegovy, Mounjaro, Zepbound: Blockbuster weight loss drugs have been arguably the biggest health story of the last several years — and there are no signs their popularity will slow down ...

The US Food and Drug Administration approved Ozempic in 2017 to treat Type 2 diabetes in adults and Wegovy in 2021 for adult weight loss. They are part of a class of drugs that mimic the GLP-1 ...

Plus: GLP-1 drugs like Ozempic have potential to treat cancer, COVID-19, heart disease, and many other diseases.

“State Medicaid programs do have to cover the drugs approved to treat diabetes,” Williams said. “So, for example, Ozempic is FDA-approved for diabetes, so Medicaid does have to cover Ozempic ...

Inflation might be easing in some segments of the economy, but health care costs are set to soar next year ... increased expenditures on specialty prescription drugs — particularly GLP-1 ...